About Us

Dan has more than 20 years of operating and advisory experience in the life sciences industry. He has served as Anaptys’ president and chief executive officer since March 2022. Previously, he was chief operating officer at Mirati Therapeutics responsible for leading the company’s corporate strategy, finance, legal and other business operations. Prior to Mirati, Dan was chief business officer at Spark Therapeutics until its acquisition by Roche. Previously, Dan was a managing director and founding member of Centerview Partner’s healthcare advisory practice. Dan’s earlier experience includes healthcare investment banking at Merrill Lynch and management consulting in the life sciences practice at PRTM. Dan earned a B.S. in engineering from Cornell University and an MBA in healthcare management from the Wharton School of the University of Pennsylvania.

Susannah Gray has more than 30 years of healthcare experience specifically in corporate finance and capital markets roles. Most recently, she spent 14 years as EVP, Finance and CFO of Royalty Pharma Management, LLC, before retiring in 2019.

Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBC World Markets’ high yield group from 2002 to 2004, and previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities).

Ms. Gray is also a member of the board of directors of 4D Molecular Therapeutics, Theravance Biopharmaceutical and Maravai Life Sciences. She also sits on the board of trustees of Wesleyan University and the Colby College Museum of Art.

Ms. Gray holds an MBA from Columbia University and a BA in social studies from Wesleyan University.

Owen Hughes is chief executive officer of XOMA Royalty, a biotech royalty company.  Prior to his tenure at XOMA Royalty, Mr. Hughes served as the CEO of Sail Bio, Inc., private biotechnology company focused on addressing ADTKD, a rare genetic kidney disease and was the co-founder and CEO Cullinan Oncology, Inc., a publicly traded oncology company.  Previously, Mr. Hughes served as the chief officer and head, Corporate Development at Intarcia Therapeutics, Inc., a biotechnology company focused on type II diabetes and obesity. Prior to his operating roles, Mr. Hughes spent 16 years on Wall Street in various capacities, including roles at Brookside Capital, an operating division of Bain Capital and Pyramis Global Advisors, a Fidelity Investments Company. Mr. Hughes currently serves on the board of directors of C4 Therapeutics and was the former chairman or lead independent director of Ikena Oncology (IKNA), Radius Health (RDUS), and Translate Bio (TBIO). Mr. Hughes received a B.A. in History from Dartmouth College.

Oleg Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, which invests in companies at all stages of research and development. With more than twenty years of experience in biotech investing, Mr. Nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities.

Before founding EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners, one of the first hedge funds dedicated to investing in the biotechnology sector. He currently also serves as a Board Member for three other publicly traded companies: Aktis Oncology (NASDAQ: AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies; Zymeworks (NASDAQ: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease; and Galapagos (Euronext & NASDAQ: GLPG).

Mr. Nodelman has a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.

John Orwin has served as a member and Chairman of our board of directors since September 2023. He served as President and Chief Executive of Officer of Relypsa, Inc., until its acquisition by the Galenica Group.

He also has served as a member of the board of directors of CARGO Therapeutics, Inc. since August 2022, and Travere Therapeutics, Inc. since March 2017. Additionally, Mr. Orwin serves as the Chair of the Board of Directors of the privately held company Nested Therapeutics, on the Board of Directors of the privately held company Ambrosia Biosciences, Inc., and as the Executive Chair of the Board of Directors of the privately held company Agni Bio, Inc., and is a Venture Partner in Samsara BioCapital. He previously served as a member of the board of directors of Seagen, Inc. since January 2014 until its acquisition by Pfizer in December 2023 and Array BioPharma, Inc. from November 2012 to July 2019.

Mr. Orwin received a BA in Economics from Rutgers, The State University of New Jersey and a MBA from New York University.

Hollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008. From 1991 to 1993, Mr. Renton served as President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, following its acquisition of Cetus Corporation. He served as President of Cetus Corporation from 1990 to 1991, as Chief Operating Officer from 1987 to 1990, and as Chief Financial Officer from 1983 to 1987. Mr. Renton serves as chairman of the board of Portola Pharmaceuticals, Inc. and serves on the board of Zymeworks, Inc. He previously served on the boards of directors of Cepheid, Inc., Kythera Biopharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., Affymax, Inc., Sangstat Medical Corporation, Special Olympics Northern California and the Biotechnology Industry Organization. Mr. Renton received a B.S. in Mathematics from Colorado State University and a M.B.A. from the University of Michigan.

John Schmid has more than 35 years of experience in financial and senior management in the biotech industry and has raised more than $900 million in private and public equity as well debt financings as a Chief Financial Officer. He has taken two companies public as a CFO and over the past six years, he has been involved in six IPOs as an independent board member. He is currently also a Board Member for Design Therapeutics (Nasdaq: DSGN), and Bright Peak Therapeutics, serving as the Audit Chair. Mr. Schmid also serves on the Boards of Forge Therapeutics and Speak, Inc.

Mr. Schmid has previously served on the boards of Poseida Therapeutics and Helix Acquisition Corp, II. Previously, he was the Chief Financial Officer of Auspex Pharmaceuticals which he joined in 2013 and took public in early 2014 before it was sold to Teva in 2015 for $3.5 billion. Prior to Auspex, Mr. Schmid co-founded Trius Therapeutics in 2004 where he served as CFO through its IPO and until its sale to Cubist Pharmaceuticals in 2013 for over $700 million. Before Trius, he was CFO of GeneFormatics and Endonetics (acquired by Medtronic) as well as an Associate with Idanta Partners, a venture capital firm, Vice President at HomeFed Bank and a Financial Analyst for Manufacturers Hanover (now part of J.P. Morgan) in New York. He is a past President and a past board member of the San Diego Venture Group.

Mr. Schmid received a BA in Economics from Wesleyan University and an MBA from the University of San Diego.